Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion type Assertion NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_head.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion description "[before RRBSO and with no clinical signs of ovarian cancer) CA125 level was 9.0 U/ml (range 2-78) and was 10.0 U/ml (range 1-43) in 115 BRCA2 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_provenance.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion evidence source_evidence_literature NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_provenance.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion SIO_000772 24389956 NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_provenance.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion wasDerivedFrom befree-20150227 NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_provenance.
- NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_assertion wasGeneratedBy ECO_0000203 NP273177.RATn7v_o7op6f8cF9O2pbxdo4fdIbWKMTY0NkaxhsTY_Q130_provenance.